- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03974360
Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache
An Open Label Study to Evaluate the Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Headache Attributed to Mild Traumatic Injury to the Head
Study Overview
Status
Intervention / Treatment
Detailed Description
The reasons and justification of choosing an open-label design are the following:
- To date, there are no evidence for prophylactic drugs treating post-traumatic headache. Post-traumatic headache patients are notoriously known to be refractory to prophylactic treatment and have usually tried several prophylactic drugs such as amitriptylin, which is recommended as a prophylactic drug in migraine and chronic tension-type headache, and other drugs developed for the treatment of primary headache disorders. First step is therefore to show if there is an effect at all following erenumab treatment in these refractory PPTH patients.
- The refractory nature of PPTH will lower the bias that could occur through placebo effects.
- The treatment period is also quite long, and the endpoint is assessed in the last month of treatment, which will also minimize a placebo effect.
- Furthermore, this relatively small exploratory open label study is needed to show if there is an effect of erenumab in post-traumatic headache at all and what this effect is, before initiating larger multicenter double-blind studies in this patient group.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Copenhagen
-
Glostrup, Copenhagen, Denmark, 2600
- Danish Headache Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between 18 - 65 years who suffer from PPTH following a concussion / mild traumatic brain injury more than 12 months ago.
- Fertile women must use safe contraceptives and present with a negative u-HCG on the experimental day. Safe contraceptives are defined as intra-uterine devices, contraceptive pills or implants and surgical sterilization.
Exclusion Criteria:
- Pre-trauma primary headache disorders, including tension-type headache > 1 days/months
- Medication-overuse headache
- Whiplash injury
- Cardiovascular disease of any kind, including cerebrovascular disease
- Hypertension on the experimental day (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
- Hypotension on the experimental day (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
- Pre-trauma psychiatric disorder of any kind - unless effectively treated
- Anamnestic or clinical symptoms of any kind that are deemed relevant for study participation by the physician who examines the patient
- Pregnant or breastfeeding, or is a female expecting to conceive during the study,
- including through 4 weeks after the last dose of erenumab
- Female subject of childbearing potential who is unwilling to use an acceptable
Method of effective contraception during treatment through 4 weeks after the last dose of erenumab. Acceptable methods of effective birth control include not having intercourse (true abstinence, when this is in line with the preferred and usual lifestyle of the subject), hormonal birth control methods (pills, shots/injections, implants, or patches), intrauterine devices, surgical contraceptive methods (vasectomy with medical assessment of the surgical success of this procedure or bilateral tubal ligation), or two barrier methods (each partner must use one barrier method) with spermicide - males must use a condom with spermicide; females must choose either a diaphragm with spermicide, OR cervical cap with spermicide, OR contraceptive sponge with spermicide. Female subjects not of childbearing potential are defined as any female who: is post-menopausal by history, defined as:
- Age ≥ 55 years with cessation of menses for 12 or more months, OR
- Age < 55 years but no spontaneous menses for at least 2 years, OR
Age < 55 years and spontaneous menses within the past 1 year, but currently amenorrheic (eg, spontaneous or secondary to hysterectomy), AND with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved. OR
- Underwent bilateral oophorectomy OR
- Underwent hysterectomy OR
- Underwent bilateral salpingectomy
- Known sensitivity to any component of erenumab
- Previously randomized into an erenumab study
- Member of investigational site staff or relative of the investigator
- Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Erenumab
100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
|
100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of Erenumab on Headache Days with Moderate or Severe Intensity
Time Frame: 12 weeks
|
To evaluate the effect of erenumab on change in the monthly average number of headache days with moderate or severe intensity from baseline to week 9-12 in patients with persistent post-traumatic headache (PPTH).
The assessment will be made using a headache diary.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erenumab on number of Headache Days
Time Frame: 12 weeks
|
To evaluate the effect of erenumab on change in the monthly average number of headache days from baseline to week 9-12 in PPTH patients.
The assessment will be made using a headache diary.
|
12 weeks
|
Proportion of Patient reaching at least 75% reduction in monthly average number of headache days
Time Frame: 12 weeks
|
To evaluate the proportion of patients reaching at least 75% reduction in the monthly average number of headache days of any severity (Time frame: baseline - week 12).
The assessment will be made using a headache diary.
|
12 weeks
|
Proportion of Patient reaching at least 50% reduction in monthly average number of headache days
Time Frame: 12 weeks
|
To evaluate the proportion of patients reaching at least 50% reduction in the monthly average number of headache days of any severity (Time frame: baseline - week 12).
The assessment will be made using a headache diary.
|
12 weeks
|
Proportion of Patient reaching at least 25% reduction in monthly average number of headache days
Time Frame: 12 weeks
|
To evaluate the proportion of patients reaching at least 25% reduction in the monthly average number of headache days of any severity (Time frame: baseline - week 12).
The assessment will be made using a headache diary.
|
12 weeks
|
Headache Impact Test (HIT-6)
Time Frame: 12 weeks
|
To evaluate the mean change in disability score, as measured by the 6-item Headache Impact Test (HIT-6) from baseline - week 12. HIT-6 consits of six items and is a global measure of adverse headache impact to assess headache severity in the previous month and change in a patient's clinical status over a short period of time. Each of the 6 questions is responded to using 1 of 5 response categories: "never," "rarely,""sometimes," "very often," or "always." For each HIT-6 item, 6, 8, 10, 11, or 13 points, respectively, are assigned to the response provided. Subjects will complete the HIT-6 monthly at each clinical visit. |
12 weeks
|
Tolerability of Erenumab will be assessed by recording number and type of adverse events
Time Frame: 12 weeks
|
To evaluate the tolerability of erenumab.
Tolerability will be assessed by recording number and type of adverse events at each follow-up visit.
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGRP induced change in AUC in responders versus non-responders*
Time Frame: 12 weeks
|
* based on data from patients involved in the CGRP provocation (Ethics Committee of the Capital Region of Denmark (H-1801147 and H-18050498).
Response is defined as patients reaching at least 50% reduction in the monthly average number of headache days of any severity from baseline to week 9-12
|
12 weeks
|
CGRP induced incidence of exacerbations in responders versus non-responders*
Time Frame: 12 weeks
|
* based on data from patients involved in the CGRP provocation (Ethics Committee of the Capital Region of Denmark (H-1801147 and H-18050498).
Response is defined as patients reaching at least 50% reduction in the monthly average number of headache days of any severity from baseline to week 9-12
|
12 weeks
|
CGRP induced change in AUC* correlated to change in number of headache days from baseline - week 9-12
Time Frame: 12 weeks
|
* based on data from patients involved in the CGRP provocation (Ethics Committee of the Capital Region of Denmark (H-1801147 and H-18050498).
Response is defined as patients reaching at least 50% reduction in the monthly average number of headache days of any severity from baseline to week 9-12
|
12 weeks
|
Headache phenotype* in responders versus non-responders
Time Frame: 12 weeks
|
*PPTH patients will be divided into patients with a migraine phenotype or a primarily tension-type headache phenotype.
Headache phenotype will be assessed using a semi-structured interview.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Headache Disorders
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Headache Disorders, Secondary
- Brain Injuries
- Brain Injuries, Traumatic
- Headache
- Post-Concussion Syndrome
- Brain Concussion
- Post-Traumatic Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Erenumab
Other Study ID Numbers
- 2018-003943-46
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-Concussion Syndrome
-
Essentia HealthUniversity of North Dakota; Dakota Medical Foundation; The Swanson Foundation; State...Active, not recruitingConcussion Post Syndrome | Persistent Post-concussive SyndromeUnited States
-
Spaulding Rehabilitation HospitalRio Grande NeurosciencesWithdrawnConcussion | Post Concussive Syndrome
-
Boston Children's HospitalCompletedPost Concussion SymptomsUnited States
-
McMaster UniversityNot yet recruitingPost Concussion Syndrome
-
Duke UniversityEnrolling by invitation
-
Children's Hospital Medical Center, CincinnatiCompletedConcussion | Post-concussion Syndrome | Sports InjuryUnited States
-
Sunnybrook Health Sciences CentreRecruitingPost Concussion SyndromeCanada
-
University Children's Hospital, ZurichUniversity of Zurich; ETH ZurichRecruiting
-
University of OttawaUnknownConcussion Post Syndrome
-
University of ArizonaWithdrawnPost Concussion SyndromeUnited States
Clinical Trials on AMG 334
-
Solvay PharmaceuticalsCompletedPharmacology, ClinicalNetherlands
-
AmgenCompleted
-
AmgenCompleted
-
AmgenCompletedMigraineUnited States
-
Charite University, Berlin, GermanyCompletedHeadache Disorders, Primary | Cluster Headache | Trigeminal Autonomic Cephalalgias | Brain DiseaseGermany
-
Messoud AshinaDanish Headache Center; Novartis Pharmaceuticals; Herlev and Gentofte HospitalUnknown
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada
-
AmgenCompletedMigraineUnited States, Denmark, France, Spain, Portugal, Russian Federation, Greece, Switzerland